The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
Neda Laiteerapong, Sandra A Ham, Yue Gao, Howard H Moffet, Jennifer Y Liu, Elbert S Huang, Andrew J Karter, Neda Laiteerapong, Sandra A Ham, Yue Gao, Howard H Moffet, Jennifer Y Liu, Elbert S Huang, Andrew J Karter
Abstract
Objective: To examine for a legacy effect of early glycemic control on diabetic complications and death.
Research design and methods: This cohort study of managed care patients with newly diagnosed type 2 diabetes and 10 years of survival (1997-2013, average follow-up 13.0 years, N = 34,737) examined associations between HbA1c <6.5% (<48 mmol/mol), 6.5% to <7.0% (48 to <53 mmol/mol), 7.0% to <8.0% (53 to <64 mmol/mol), 8.0% to <9.0% (64 to <75 mmol/mol), or ≥9.0% (≥75 mmol/mol) for various periods of early exposure (0-1, 0-2, 0-3, 0-4, 0-5, 0-6, and 0-7 years) and incident future microvascular (end-stage renal disease, advanced eye disease, amputation) and macrovascular (stroke, heart disease/failure, vascular disease) events and death, adjusting for demographics, risk factors, comorbidities, and later HbA1c.
Results: Compared with HbA1c <6.5% (<48 mmol/mol) for the 0-to-1-year early exposure period, HbA1c levels ≥6.5% (≥48 mmol/mol) were associated with increased microvascular and macrovascular events (e.g., HbA1c 6.5% to <7.0% [48 to <53 mmol/mol] microvascular: hazard ratio 1.204 [95% CI 1.063-1.365]), and HbA1c levels ≥7.0% (≥53 mmol/mol) were associated with increased mortality (e.g., HbA1c 7.0% to <8.0% [53 to <64 mmol/mol]: 1.290 [1.104-1.507]). Longer periods of exposure to HbA1c levels ≥8.0% (≥64 mmol/mol) were associated with increasing microvascular event and mortality risk.
Conclusions: Among patients with newly diagnosed diabetes and 10 years of survival, HbA1c levels ≥6.5% (≥48 mmol/mol) for the 1st year after diagnosis were associated with worse outcomes. Immediate, intensive treatment for newly diagnosed patients may be necessary to avoid irremediable long-term risk for diabetic complications and mortality.
© 2018 by the American Diabetes Association.
Figures
References
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589
- de Boer IH, Rue TC, Cleary PA, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group . Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011;171:412–420
- Nathan DM, Cleary PA, Backlund JY, et al. .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
- Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–693
- Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618–1620
- Laiteerapong N, Karter AJ, Moffet HH, et al. . Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study. J Diabetes Complications 2017;31:94–100
- Karter AJ, Parker MM, Moffet HH, et al. . Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care 2004;42:110–115
- Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519–2527
- Karter AJ, Schillinger D, Adams AS, et al. . Elevated rates of diabetes in Pacific Islanders and Asian subgroups: The Diabetes Study of Northern California (DISTANCE). Diabetes Care 2013;36:574–579
- Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: The Diabetes and Aging Study. Diabetes Care 2011;34:1329–1336
- Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: The Diabetes and Aging Study. JAMA Intern Med 2014;174:251–258
- Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: The Diabetes & Aging Study. Diabetes Care 2014;37:3188–3195
- Lipska KJ, Warton EM, Huang ES, et al. . HbA 1c and risk of severe hypoglycemia in type 2 diabetes: The Diabetes and Aging Study. Diabetes Care 2013;36:3535–3542
- Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518–523
- Sacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA 2014;311:2271–2272
- NGSP Factors that interfere with HbA1c test results [Internet], 2017. Available from . Accessed 2 January 2018
- Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251
- Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100.
- Osataphan S, Chalermchai T, Ngaosuwan K. Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: a retrospective cohort study. J Diabetes 2017;9:267–274
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820
- Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410–415
- Genuth S, Sun W, Cleary P, et al. .; DCCT Skin Collagen Ancillary Study Group . Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103–3111
- Ali MK, McKeever Bullard K, Imperatore G, Barker L, Gregg EW; Centers for Disease Control and Prevention (CDC) . Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes--National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Suppl 2012;61(Suppl.):32–37
- Hayward RA, Reaven PD, Wiitala WL, et al. .; VADT Investigators . Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197–2206
- Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184–2189
- Blumenthal KJ, Larkin ME, Winning G, Nathan DM, Grant RW. Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res 2010;10:158.
- Gregg EW, Li Y, Wang J, et al. . Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514–1523
- Harris MI, Cowie CC, Eastman R. Health-insurance coverage for adults with diabetes in the U.S. population. Diabetes Care 1994;17:585–591
- McCarthy D, Mueller K, Wrenn J. Kaiser Permanente: Bridging the Quality Divide with Integrated Practice, Group Accountability, and Health Information Technology. New York, NY, The Commonwealth Fund, 2009
Source: PubMed